Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer.
作者信息
Jacky Jennifer, Baik Christina
机构信息
Seattle Cancer Care Alliance and Department of Medicine (Medical Oncology Division), University of Washington, Seattle, Washington; and Department of Medicine (Medical Oncology Division), University of Washington School of Medicine, Seattle, Washington.
出版信息
J Adv Pract Oncol. 2017 Nov-Dec;8(7):729-735. Epub 2017 Nov 1.
Abstract
摘要
相似文献
1
Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer.接受间变性淋巴瘤激酶抑制剂治疗的非小细胞肺癌患者的症状管理策略
J Adv Pract Oncol. 2017 Nov-Dec;8(7):729-735. Epub 2017 Nov 1.
2
Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.非小细胞肺癌中间变性淋巴瘤激酶抑制剂的临床药代动力学。
Clin Pharmacokinet. 2019 Apr;58(4):403-420. doi: 10.1007/s40262-018-0689-7.
3
Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.利用药效团信息学策略发现强效ALK抑制剂
Cell Biochem Biophys. 2018 Jun;76(1-2):111-124. doi: 10.1007/s12013-017-0800-y. Epub 2017 May 6.
4
An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report.1例间变性淋巴瘤激酶阳性肺癌短期内病情加重的尸检病例报告
J Med Case Rep. 2019 Apr 29;13(1):118. doi: 10.1186/s13256-019-2054-3.
5
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.间变性淋巴瘤激酶抑制剂在非小细胞肺癌中的安全性和耐受性。
Drug Saf. 2019 Feb;42(2):199-209. doi: 10.1007/s40264-018-0771-y.
6
Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis.一名长期存活的间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌伴软脑膜癌转移患者接受四线ALK抑制剂治疗及脑部放疗的情况
Anticancer Drugs. 2019 Feb;30(2):201-204. doi: 10.1097/CAD.0000000000000699.
7
Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.一名体能状态较差的ALK重排肺癌患者对阿来替尼产生显著反应。
BMC Res Notes. 2016 Mar 17;9:173. doi: 10.1186/s13104-016-1983-9.
8
Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.间变性淋巴瘤激酶作为治疗间变大细胞淋巴瘤、非小细胞肺癌和神经母细胞瘤的靶点。
Anticancer Agents Med Chem. 2010 Mar;10(3):236-49. doi: 10.2174/1871520611009030236.
9
Ceritinib: A primer for pharmacists.色瑞替尼：药剂师入门指南。
J Oncol Pharm Pract. 2017 Dec;23(8):602-614. doi: 10.1177/1078155216672315. Epub 2016 Oct 13.
10
Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.间变性淋巴瘤激酶阳性非小细胞肺癌的诊断与治疗
Hematol Oncol Clin North Am. 2017 Feb;31(1):101-111. doi: 10.1016/j.hoc.2016.08.012.
引用本文的文献
1
A comparison of mRNA and circRNA expression between squamous cell carcinoma and adenocarcinoma of the lungs.肺鳞状细胞癌和腺癌之间mRNA与环状RNA表达的比较。
Genet Mol Biol. 2020 Oct 6;43(4):e20200054. doi: 10.1590/1678-4685-GMB-2020-0054. eCollection 2020.
本文引用的文献
1
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.奥氮平用于预防化疗引起的恶心和呕吐。
N Engl J Med. 2016 Jul 14;375(2):134-42. doi: 10.1056/NEJMoa1515725.
2
Cannabinoids for Symptom Management and Cancer Therapy: The Evidence.大麻素用于症状管理和癌症治疗：证据。
J Natl Compr Canc Netw. 2016 Jul;14(7):915-22. doi: 10.6004/jnccn.2016.0094.
3
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.针对晚期ALK阳性非小细胞肺癌患者使用色瑞替尼时潜在胃肠道不良反应的积极管理策略。
Cancer Manag Res. 2016 Mar 24;8:33-8. doi: 10.2147/CMAR.S96471. eCollection 2016.
4
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.色瑞替尼在间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者中的活性与安全性（ASCEND-1）：多中心、开放标签、1期试验的更新结果
Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.
5
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.克唑替尼治疗后进展的间变性淋巴瘤激酶阳性非小细胞肺癌患者中阿来替尼的疗效：一项全球 II 期研究。
J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23.
6
Morphological distribution of lung cancer from Cancer Incidence in Five Continents Vol. X.《五大洲癌症发病率》第十卷中肺癌的形态学分布
Jpn J Clin Oncol. 2015 Apr;45(4):404. doi: 10.1093/jjco/hyv041.
7
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
8
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
9
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
10
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.ALK 阳性非小细胞肺癌患者中克唑替尼的活性和安全性：来自一项 I 期研究的更新结果。
Lancet Oncol. 2012 Oct;13(10):1011-9. doi: 10.1016/S1470-2045(12)70344-3. Epub 2012 Sep 4.
Zotero 插件